Medicare

Exclusive Nicholas Florko

Warren, Grassley threaten to slap FDA with a 30-day deadline for OTC hearing aid rules

First Opinion John N. Mafi and Catherine Sarkisian

Medicare got it right: Unproven Alzheimer’s drug would have threatened the financial stability of 60 million Americans

Politics Rachel Cohrs

Medicare finalizes its restrictions on new Alzheimer’s drug, despite pressure from drugmakers

Pharmalot Ed Silverman

Many Medicare Part D beneficiaries don’t fill prescriptions for high-priced medicines

First Opinion David C. Grabowski, Marilyn Rantz and Jasmine L. Travers

Report: U.S. nursing home care is ineffective, inefficient, inequitable, fragmented, and unsustainable

D.C. Diagnosis Nicholas Florko

Faced with high drug prices, seniors are abandoning cancer drugs at the pharmacy

First Opinion Constantinos Michaelidis and Candra Szymanski

Home care instead of hospital care: Congress should extend a crucial waiver

Insurance Bob Herman

Biden administration funnels one of the largest-ever pay increases to Medicare Advantage insurers

Insurance Bob Herman and Tara Bannow

UnitedHealth’s deal with LHC highlights broader interest in home health industry

First Opinion Amol Navathe, Risa Lavizzo-Mourey and Joshua Liao

How to fix the two-tier U.S. health payment system

Politics Rachel Cohrs

Medicare premiums could decrease ‘soon,’ after decision on Alzheimer’s drug Aduhelm

D.C. Diagnosis Nicholas Florko

Inside the push for a permanent pandemic preparedness office at the White House

Politics Rachel Cohrs

Congress considers a longer phase-out of looser, Covid-era telehealth policies

Business Bob Herman

Even as it struggles, startup insurer Bright Health deepens its ties to Cigna

First Opinion Ge Bai and David A. Hyman

Nonprofit hospitals’ community benefits should square with their tax exemptions. They often don’t

Biotech Nicholas Florko

Biogen pushes back on Medicare’s limits on Alzheimer’s drug coverage — and advances a counteroffer

Politics Nicholas Florko

The unexpected forces behind thousands of comments about Medicare’s limits on a new Alzheimer’s drug

First Opinion Linda H. Aiken and Claire M. Fagin

Medicare can help fix the nurse shortage in hospitals

First Opinion Caroline Behr and Michael L. Barnett

High-risk individuals should get priority access to Covid therapies. That isn’t happening

Politics Rachel Cohrs

No one has any idea how much money seniors could pay for new Alzheimer’s drug

Exclusive Damian Garde and Adam Feuerstein

With its Alzheimer’s drug in turmoil, Biogen eyes a list of potential acquisitions

Health Nicholas Florko

With its Aduhelm proposal, Medicare is stepping into a heated debate about how best to improve equity in Alzheimer’s treatment

Matt's Take Matthew Herper

Why Biogen’s Medicare mess is bad for the pharmaceutical industry

Politics Rachel Cohrs

Medicare plans to restrict access to controversial, pricey Alzheimer’s drug Aduhelm to patients in clinical trials

Politics Rachel Cohrs

Becerra orders Medicare to reconsider premium hike following price drop for Biogen’s Aduhelm

Pharmalot Ed Silverman

A looming decision on Medicare coverage for Biogen’s Alzheimer’s drug could shock state Medicaid programs

Pharmalot Rachel Cohrs and Ed Silverman

Biden administration poised to give pharmacies a major lobbying win

First Opinion Reshma Ramachandran, Tianna Zhou and Joseph S. Ross

Out-of-pocket drug costs for Medicare beneficiaries need to be reined in

First Opinion Sterling N. Ransone, Jr.

Clinical labor pricing updates are needed to address workforce shortages, financial strain